Efficacy of Tongguanteng Injection combined with GC regimen in the treatment of advanced NSCLC and its influence on peripheral blood T lymphocyte subsets
XIU Junqing1 LI Liang2 LIU Rui3
1.Department of Oncology, Guang’anmen Hospital South District, China Academy of Traditional Chinese Medicine, Beijing 102600, China;
2.Department of Ultrasound, Guang’anmen Hospital, China Academy of Traditional Chinese Medicine, Beijing 100053;
3.Department Oncology, Guang’anmen Hospital, China Academy of Traditional Chinese Medicine, Beijing 100053
[Abstract] Objective To investigate the efficacy of Tongguanteng Injection combined with GC regimen in the treatment of advanced non-small cell lung cancer (NSCLC) and its influence on peripheral blood T lymphocyte subsets. Methods Seventy patients with NSCLC treated in the Department of Oncology, Guang’anmen Hospital Southern District, China Academy of Traditional Chinese Medicine from March 2020 to March 2021 were selected and they were divided into control group and study group according to the random number table method, with 35 patients in each group. The control group was treated with GC alone, and the study group was treated with GC + Tongtengteng Injection. The adverse reactions of the two groups were recorded, the short-term efficacy was evaluated, and the changes of T lymphocyte subsets and quality of life were observed. Results The short-term efficacy of the study group was better than the control group, and the objective remission rate was higher than the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in disease control rate between the two groups (P ＞ 0.05). After two cycles of treatment, the proportion of CD3+, CD4+ and CD4+/CD8+ in both groups increased, and those in the study group were higher than the control group, and the proportion of CD8+ was decreased, and the study group was lower than the control group, the differences were statistically significant (P ＜ 0.05). After two cycles of treatment, KPS score of both groups increased and the study group was higher than the control group, the differences were statistically significant (P ＜ 0.05). Compared with the control group, the incidence of grade Ⅲ-Ⅳ nausea and vomiting and grade Ⅲ-Ⅳ leukopenia was significantly decreased in the study group, while the incidence of grade Ⅰ-Ⅱ leukopenia was increased, and the differences were statistically significant (P ＜ 0.05). Conclusion Tongguanteng Injection and combined GC regimen in the treatment of advanced NSCLC can achieve better short-term efficacy, improve the distribution of T lymphatic subgroups, promote the recovery of immune function, reduce the side effects of chemotherapy, and improve the quality of life of patients, which is worthy of clinical reference.
修俊青1 李亮2 刘瑞3. 通关藤注射液联合GC方案治疗晚期NSCLC的效果及对外周血T淋巴细胞亚群的影响[J]. 中国医药导报, 2022, 19(14): 101-104.
XIU Junqing1 LI Liang2 LIU Rui3. Efficacy of Tongguanteng Injection combined with GC regimen in the treatment of advanced NSCLC and its influence on peripheral blood T lymphocyte subsets. 中国医药导报, 2022, 19(14): 101-104.
京公网安备 11010502046598号